LabCompass

Samuel Cataland

Medicine · The Ohio State University

OpenAlex
Established · publishing since 1974
Diabetes Treatment and ManagementNeuropeptides and Animal PhysiologyHelicobacter pylori-related gastroenterology studiesGastroesophageal reflux and treatmentsNeuroendocrine Tumor Research Advances

Publications

81

Citations

2,470

Est. group size

—

Recurring co-author estimate

Active years

51

Publishing since 1974

Research summary
AI-generated

Samuel Cataland's work focuses on a rare blood clotting disorder called acquired thrombotic thrombocytopenic purpura (aTTP), studying treatments such as the drug caplacizumab combined with plasma exchange and immune-suppressing therapy. His publications draw on data from large international clinical trials (such as the HERCULES trial) examining the safety, effectiveness, and long-term outcomes of these treatments.

Thrombotic thrombocytopenic purpura (TTP)Caplacizumab therapyPlasma exchange treatmentBlood clotting disordersClinical trial outcomes research

Publication output has been low and irregular over the last decade, with a small cluster of outputs appearing in 2020, 2022, and 2024 and no publications in other years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 0.4/year recently
1718192020: 2 publications220212022: 1 publication22232024: 1 publication242526
Recent publications
Publishes in
  • Hematology Transfusion and Cell Therapy×2
  • HemaSphere×1
  • La Revue de Médecine Interne×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile